Literature DB >> 19007840

WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland.

Morag Ferguson1, Dianna E Wilkinson, TieQun Zhou.   

Abstract

In anticipation of the implementation of new prophylactic HPV vaccines, the WHO is supporting the establishment of a global WHO HPV Laboratory Network whose mission is to "contribute to improving the quality of laboratory services for effective surveillance and monitoring of HPV vaccination impact through enhanced, state-of-the-art laboratory support". WHO convened a meeting at its headquarters, 24-25 January 2008 which placed particular emphasis on the harmonization of HPV Laboratory Network practices and standardization of HPV assays as these are crucial for the success of the HPV Laboratory Network in conducting studies measuring HPV disease burden and vaccine impact. To assist the HPV Laboratory Network in fulfilling its mission, the meeting was attended by all members of the HPV Laboratory Network, representatives of WHO Headquarters and Regional Offices, WHO Collaborating Centres involved in HPV-related work as well as experts from additional HPV laboratories around the world, representatives of national regulatory and control authorities, non-profit organizations and the vaccine industry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007840     DOI: 10.1016/j.vaccine.2008.10.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

3.  Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Authors:  Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

4.  Serum antibody response following genital {alpha}9 human papillomavirus infection in young men.

Authors:  Zoe R Edelstein; Joseph J Carter; Ruchi Garg; Rachel L Winer; Qinghua Feng; Denise A Galloway; Laura A Koutsky
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

5.  Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.

Authors:  Ali Rowhani-Rahbar; Frances B Alvarez; Janine T Bryan; James P Hughes; Stephen E Hawes; Noel S Weiss; Laura A Koutsky
Journal:  J Clin Virol       Date:  2011-12-30       Impact factor: 3.168

6.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

7.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.

Authors:  Lara F Bratcher; Vikrant V Sahasrabuddhe
Journal:  Infect Agent Cancer       Date:  2010-05-12       Impact factor: 2.965

8.  Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.

Authors:  Holly J Corbett; Germain J P Fernando; Xianfeng Chen; Ian H Frazer; Mark A F Kendall
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

9.  Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.

Authors:  Tsung-Chieh Jane Fu; Joseph J Carter; James P Hughes; Qinghua Feng; Stephen E Hawes; Stephen M Schwartz; Long Fu Xi; Taylor Lasof; Joshua E Stern; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Int J Cancer       Date:  2016-08-04       Impact factor: 7.396

10.  Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men.

Authors:  Rachna Sharma; Jimmy T Efird; Aung Chein; Elizabeth A Holly; Mel Krajden; J Michael Berry; Teresa M Darragh; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.